Episode
What’s New and What’s Next in CLL
- Podcast
- Treating Blood Cancers
- Published
- Feb 17, 2026
- Duration seconds
- 2359
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/what-s-new-and-what-s-next-in-cll/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/treating-blood-cancers-14318/what-s-new-and-what-s-next-in-cll.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Brad Kahl, MD, Siteman Cancer Center, St. Louis MO Recorded on January 27, 2026 Brad Kahl, MD Professor of Medicine Division of Oncology, Department of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St. Louis, MO In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients